Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab ...

Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan. 1 The ...

The government agency says X no longer suits its communication needs.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

Campaign encourages the use of low-dose aspirin to help reduce the risk of preeclampsia and the complications that come with ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Veeva’s vice president of commercial strategy discusses how streamlining their processes with a single goal in mind can ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...